Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28923161 | 0.85 | LMNA (0.43) | LMNAMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL20323654 | 0.85 | LMNA (0.43) | LMNAMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL13621140 | 0.79 | MEN1 (0.48) | LMNAMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL12634 | 0.79 | KDM4E (0.53) | LMNAMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL8263007 | 0.77 | KDM4E (0.65) | LMNAMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL8263008 | 0.77 | MEN1 (0.47) | LMNAMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL2913421 | 0.77 | KDM4E (0.50) | LMNAMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL24572139 | 0.74 | CHRNA7 (0.33) | — | |
| SCHEMBL14971519 | 0.73 | MEN1 (0.44) | LMNAMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL15978962 | 0.73 | MEN1 (0.44) | LMNAMEN1KMT2ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353835-A1 | N-TETRAZOLYL ARYL UREA-BASED DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | HANGZHOU YIRUI PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2025-11-20 | — | — | US | disclosed |
| CN-120192251-A | Sulfonamide compound for resisting prostate cancer and application thereof | 浙江大学 | 2025-06-24 | — | — | CN | disclosed |
| EP-4538261-A1 | N-TETRAZOLYL ARYL UREA DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | Hangzhou Yirui Pharmaceutical Technology Co., Ltd. (CN) | 2025-04-16 | — | — | EP | disclosed |
| CN-117229258-B | N-tetrazolyl aryl urea derivative and preparation method and application thereof | 杭州壹瑞医药科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-117229258-A | N-tetrazolyl aryl urea derivative and preparation method and application thereof | 杭州壹瑞医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX-FXR GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| EP-2970215-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-9656955-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
| EP-2188272-A2 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV Remynd (BE) | 2010-05-26 | — | — | EP | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| WO-2009019295-A2 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-12 | — | — | WO | disclosed |
| US-6194438-B1 | ANTITUMOR AGENTS; ANTICANCER AGENTS; FARNESYL-PROTEIN TRANSFERASE INHIBITOR | PFIZER INC. | 2001-02-27 | — | — | US | disclosed |
| EP-1006113-A1 | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth | Pfizer Products Inc. (US) | 2000-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | LMNA 1113/4885MEN1 799/4885KMT2A 1844/4885 |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | LMNA 80/4885MEN1 454/4885KMT2A 2680/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | LMNA 1113/4885MEN1 799/4885KMT2A 1844/4885 |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | LMNA 1407/4885MEN1 4789/4885KMT2A 2026/4885 |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | LMNA 1407/4885MEN1 4789/4885KMT2A 2026/4885 |
| US-20250353835-A1 | N-TETRAZOLYL ARYL UREA-BASED DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | BDKRB1, BDKRB2, UTS2R | LMNA 2057/4885MEN1 1907/4885KMT2A 2463/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | LMNA 1113/4885MEN1 799/4885KMT2A 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.